By Brazil Stock Guide – Oncoclínicas do Brasil Serviços Médicos (ONCO3) has entered a governance rupture after the resignation of Chairman Marcelo Gasparino, which triggered the automatic removal of the entire board under Brazil’s cumulative voting system.
The company said a new board will be elected at an extraordinary shareholder meeting scheduled for April 30, turning what would normally be a governance process into a critical step for its financial stabilization.
At the same time, MAK Capital, which holds 6.305% of voting shares, has nominated four independent candidates — Mateus Affonso Bandeira, Ademar Vidal Neto, Marcos Grodetzky and Raul Rosenthal Ladeira de Matos — positioning itself at the center of the board’s recomposition.
The key detail, however, sits outside the formal filing. In a letter to the company, the investor made clear that the election of its nominees is a condition for any capital injection. Governance, in this context, becomes the mechanism that unlocks — or blocks — funding.
Governance as leverage
The sequence of events — chairman resignation, full board collapse and coordinated nominations — points to a structured reallocation of power rather than an isolated change.
The profiles of the nominees reinforce that reading. Bandeira led telecom group Oi through restructuring, while Vidal Neto has been involved in high-stakes control disputes across major Brazilian corporates. The proposed board is not neutral — it is built for a stressed scenario.
By tying funding to board composition, MAK Capital is using governance as a direct lever of influence. The move shifts the company’s decision-making center at a critical juncture and suggests that any path forward will depend on a redesigned board.